3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Genitourinary
1
Conditions
Urinary Bladder Neoplasms
157
Carcinoma, Transitional Cell
56
Non-Muscle Invasive Bladder Neoplasms
30
Urethral Neoplasms
24
Carcinoma, Renal Cell
23
Neoplasms
19
Kidney Neoplasms
15
Pancreatic Neoplasms
14
Ovarian Neoplasms
14
Neoplasm Metastasis
13
Carcinoma, Non-Small-Cell Lung
13
Prostatic Neoplasms
12
Ureteral Neoplasms
11
Urologic Neoplasms
9
Colorectal Neoplasms
9
Breast Neoplasms
9
Lung Neoplasms
7
Testicular Neoplasms
6
Stomach Neoplasms
6
Melanoma
6
Sarcoma
5
Urothelial Cancer
4
Squamous Cell Carcinoma of Head and Neck
4
Small Cell Lung Carcinoma
4
Osteosarcoma
4
Colonic Neoplasms
4
Urogenital Neoplasms
3
Triple Negative Breast Neoplasms
3
Recurrence
3
Parkinson Disease 4, Autosomal Dominant Lewy Body
3
Interventions
Mitomycin
3
vofatamab
2
pembrolizumab
2
Standard of Care
2
Cystectomy
2
B701 protein, Human herpesvirus 6
2
valrubicin
1
trifluridine tipiracil drug combination
1
testosterone 17 beta-cypionate
1
palbociclib
1
enfortumab vedotin
1
atezolizumab
1
Water
1
Valsartan
1
Urinary Diversion
1
Tranexamic Acid
1
Therapeutics
1
Testosterone Propionate
1
Sunitinib
1
Stents
1
Radiosurgery
1
Radiation Dose Hypofractionation
1
Practice Guidelines as Topic
1
Nephrotomy
1
Nephrostomy, Percutaneous
1
Methyltestosterone
1
Immune Checkpoint Inhibitors
1
Ice
1
Hydroxychloroquine
1
Health Information Exchange
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Urologic Diseases
×
Gemcitabine
×
Genitourinary
×
Clear all
NCT07566156
2026-05-11
EV-309
Astellas Pharma Inc
Phase 3
Recruiting
390 enrolled